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Objective Previous studies describing menses duration and
heaviness of flow during the menopausal transition (MT) have been
short in duration and limited to white women. We estimated the
frequency of and risk factors for prolonged bleeding, spotting and
heavy bleeding during the MT in an ethnically diverse population.
Design Prospective community-based cohort study.
Setting USA: southeastern Michigan, northern California and Los
Angeles, California.
Population A total of 1320 midlife women who participated in the
Study of Women’s Health Across the Nation (SWAN) Menstrual
Calendar Substudy. Participants included African-American, white,
Chinese, and Japanese women.
Methods Women completed daily menstrual calendars from 1996
to 2006, and provided information on hormone therapy, smoking
and physical activity. Annual measures included height and
weight. Kaplan–Meier survival analysis and multivariable
regression were used to analyse the data.
Main outcome measures Menses of 10+ days, spotting of 6+ days,
heavy bleeding of 3+ days.
Results At least three occurrences of menses 10+ days was
reported by 77.7% (95% confidence interval [95% CI] 56.7–93.2),
of 6+ days of spotting by 66.8% (95% CI 55.2–78.0) and of
3+ days of heavy bleeding by 34.5% (95% CI 30.2–39.2) of
women. Menses of 10+ days, 6+ days of spotting, and 3+ days of
heavy bleeding were associated with MT stage, uterine fibroids,
hormone use and ethnicity. Body mass index was associated with
3+ days of heavy bleeding.
Conclusions These data provide clinicians and women with
important information about the expected frequency of prolonged
and heavy bleeding and spotting during the menopausal transition
that may facilitate clinical decision making.
Keywords Abnormal uterine bleeding, menopausal transition,
menopause, menstruation.
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Introduction
Gynecological disorders, including abnormal uterine bleed-
ing, are a major cause of inpatient hospital admissions in
the USA, accounting for 14% of all hospitalisations among
women aged 45–54 years old from 1998 through to 2005.1
The annual direct cost of treating abnormal uterine bleed-
ing is estimated to be US$ 1 billion.2 While the burden of
abnormal uterine bleeding is substantial, consensus has
only recently been reached on proper terminology and
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definitions, as proposed by the International Federation of
Gynecology and Obstetrics (FIGO) Menstrual Disorders
Working Group.3–6
The FIGO system classifies bleeding into nine categories
based on underlying structural and nonstructural features.5
Suggested definitions for normal menstrual bleeding in the
midreproductive years included duration of menstrual flow
between 4.5 and 8 days.3,6 Previous recommendations
defined prolonged menstrual bleeding as 10 or more days7
or menses exceeding 14 days.8
Chronic abnormal uterine bleeding, defined as abnormal
volume, regularity or timing for a period of 6 months,
associated with ovulatory dysfunction may occur with some
frequency in the late reproductive years and the meno-
pausal transition (MT) as a consequence of increased fre-
quency of ovulation and altered patterns of progesterone
production.5,6,9–12 However, data on the bleeding experi-
ence of women at the end of reproductive life is limited,
although the greater variability in menstrual bleeding pat-
terns after age 40 is well recognised.13–15
The classic study by Hallberg et al. of menses volume
demonstrated that 50-year-old women have a higher med-
ian menstrual blood flow than younger women.16 Two
European studies, of 1-year duration, have reported the
cumulative incidence of 10+ days of bleeding to be 14.7%17
and the period prevalence to be 36–49%,18 while the cumu-
lative incidence of heavy periods was 53%.18 Previous peri-
menopausal studies of menses,17–20 which included mostly
white participants, were short in duration and unable to
characterise bleeding during the whole MT.
This paper describes the distribution of menses duration
and heaviness of flow (number of heavy days, number of
spotting days) during the MT based on data from prospec-
tively collected menstrual diaries in a large, multi-ethnic
cohort of women. It also assesses the association of race/
ethnicity and body mass index (BMI) with these menstrual
bleeding characteristics.
Methods
This study used data from The Study of Women’s health
Across the Nation (SWAN), a prospective cohort study of
midlife women living in the USA. It was restricted to three
SWAN sites that conducted a menstrual calendar substudy:
northern California, Los Angeles and southeastern Michi-
gan. The design of SWAN’s cohort study has been
previously described.21 Eligibility included age 42–52 years,
self-designation as a member of the specified racial/ethnic
groups, having an intact uterus and, in the 3 months prior
to screening, having had at least one menstrual period and
not currently using exogenous hormones affecting ovarian
function, i.e. hormone therapy or hormonal contraceptives.
Each site recruited white women and women from one
minority group (African-Americans in southeastern Michi-
gan, Japanese in Los Angeles, and Chinese in northern Cal-
ifornia); a total of 1498 women were enrolled into the
cohort at the three study sites. Institutional Review Boards
at each study site approved the study protocol and all par-
ticipants provided written informed consent.
The SWAN cohort study began in 1996; baseline and
annual follow-up visits consisted of interviewer-adminis-
tered and self-administered questionnaires and height and
weight measurements.
A self-administered daily menstrual calendar began in
1996 and continued through to 2006. Heaviness of flow was
recorded using the following prespecified categories: spot-
ting (bleeding not requiring the use of a sanitary product or
not filling a regular-sized sanitary product); light to moder-
ate bleeding (sanitary protection was required but only
needed changing a few times a day or every 3–4 hours); or
very heavy bleeding (needing to change sanitary product
every 1–2 hours for more than 4 hours during the day).22
Each month women answered questions about hormone
use, gynaecological procedures, cigarette use and physical
exercise. Women completed monthly calendars for 2 years
after their final menstrual period (FMP).
Menstrual cycle length was calculated using bleeding defi-
nitions recommended by the World Health Organiza-
tion23,24 as adapted for perimenopausal women by the
ReSTAGE Collaboration,25–27 which include the require-
ment of a bleed-free interval of at least 3 days. A menstrual
cycle consisted of a bleeding episode and subsequent bleed--
free interval of at least 3 days. A bleeding episode (menses)
was defined as at least 1 day of bleeding or spotting. A
bleeding episode could contain two consecutive bleed-free
days between bleeding days. The duration of bleeding, total
number of spotting days recorded, and total number of
heavy days recorded were determined for each bleeding epi-
sode. We defined the cut-off for prolonged menses
(10+ days), spotting (6+ days) and heavy bleeding (3+ days)
by the upper 5th centile of their respective distributions. We
also used two additional definitions of prolonged menses:
the FIGO definition of menses exceeding 8 days3,6 and the
definition based on data from the World Health Organiza-
tion of menses exceeding 2 weeks (15+ days).8
Onset of the early MT and late MT were defined from
the calendar data using the STRAW + 10 definitions.9–12
Early MT was defined by the persistent difference of at least
7 days in the length of consecutive menstrual cycles. Persis-
tence was defined as recurrence within ten cycles of the
first variable length cycle. Menstrual cycles before the onset
of the early MT were defined as premenopausal. Late MT
was defined as the first occurrence of a menstrual cycle
length of at least 60 days. The FMP was defined as the first
day of a menses followed by at least 12 months of amenor-
rhoea. If neither the onset of the early MT nor the onset of
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the late MT was observed for a woman, then all of her
menstrual cycles were defined as of unknown stage.
Menstrual cycles were coded as treated cycles for all
cycles during which women reported hormone use. For
months with missing hormone information, menstrual
cycles were coded as not treated if the menstrual cycle
occurred before the first report of hormone therapy use, if
the woman reported no hormone therapy use in the calen-
dar year of the missing information or if a woman never
reported hormone therapy use.
Race/ethnicity was self-defined as African-American,
Chinese, Japanese or white. Highest education (high school
graduate or less than high school versus at least some col-
lege) and marital status (single, married/partnered, or sepa-
rated, widowed, or divorced) were assessed at baseline.
Economic strain was assessed at baseline with the question
‘how hard is it to pay for basics?’ and categorised as very
hard, somewhat hard, or not hard. For each menstrual cycle,
weight was linearly interpolated between the previous and
subsequent annual visits and BMI was categorised as normal
weight (≤24.9 kg/m2), overweight (25.0–29.9 kg/m2), or
obese (≥30.0 kg/m2). The 47 women with BMI < 18.5 were
included in the normal weight category. Results do not dif-
fer when they are excluded.
A woman was considered diabetic if she self-reported
diabetes, was taking medication for diabetes, or had an
annual visit (baseline, visit 1 and visits 3–7) fasting serum
glucose level of ≥126 mg/dl (≥7 mmol/l). Uterine fibroids
were based on self-reported diagnosis. Current cigarette use
(yes/no) was defined by whether the woman reported hav-
ing smoked at least one cigarette a day or a total of 30 cig-
arettes in the last month. Baseline smoking status was
assessed by interview at the start of the study. Average
hours of physical activity per week were calculated based
on the average number of times per week and the average
number of minutes per episode of moderate to vigorous
physical activity reported.
Statistical analyses
Of the 1498 women enrolled at the three SWAN sites, 1320
(88.2%) were eligible, defined as having at least one men-
strual cycle recorded in the menstrual calendar without
hormone use, and were included in this analysis. Menstrual
cycles during hormone use and during a 1 month wash-out
period were excluded (n = 4266), as were menstrual cycles
during pregnancy or where pregnancy was suspected
(n = 30), and menstrual cycles with missing covariate
information (n = 4266). Post-hysterectomy or post-FMP
bleeding events were also excluded. Statistical analyses were
performed using SAS 9.2 (SAS Institute Inc., Cary, NC,
USA). To determine the number of women who had men-
strual events, cumulative percentages and associated 95%
confidence intervals were calculated using Kaplan–Meier
methods for survival probabilities to account for differen-
tial duration of observation and right-censoring. Time to
bleeding event was calculated from the start of the MT
stage until the first, second, or third occurrence of a bleed-
ing event for that MT stage. For women without an event,
time was calculated from start of the MT stage until the
last menses recorded during that stage. For the all-stages
analysis, time to bleeding event was calculated from the
start of the study until the first, second or third occurrence
of a bleeding event regardless of stage. For women without
an event, time was calculated from study start until the last
menses recorded in the menstrual calendar study.
Since the distribution of menses duration during the MT
is right-skewed, the median is more informative about cen-
tral tendency than the mean. We used quantile regression28
to examine factors associated with the median duration of
menses. Quantile regression models evaluate factors associ-
ated with the percentile (or quantile) of interest. Quantile
regression coefficients are interpreted similarly to linear
regression coefficients from a linear regression. For exam-
ple, the coefficients of a categorical predictor represent the
difference in menses duration in days for the 50th centile
between one category and the reference group, adjusted for
all other covariates in the model. Bootstrap sampling with
500 repetitions based on samples of women was conducted
to construct 95% confidence intervals. The multivariable
model included MT stage, ethnicity and BMI as well as co-
variates associated in the crude analysis (at P < 0.20) with
menses duration.
Generalised estimating equation methods with a first-or-
der autoregressive working correlation structure, selected
by using the quasi-likelihood information criterion, were
used to model the association between menses of 10+ days
duration, heavy bleeding of 3+ days, or 6+ days of spotting
and covariates. Multivariable models included MT stage,
ethnicity and BMI as well as covariates associated in the
crude analysis (at P < 0.20). In order to examine the asso-
ciation with study site, multivariable models were run
among white women with study site as a variable instead
of race/ethnicity.
Results
Women who were excluded were more likely to be from
southeastern Michigan, African-American, report low edu-
cational attainment and economic strain, be overweight/
obese, be a current smoker, and be less likely to be married
than were included women (Table 1).
Of the 1320 eligible women, 963 (73.0%) had onset of
the early MT identified and 815 (61.7%) had onset of late
MT identified. In all, 431 (32.7%) women had their FMP
identified in the menstrual calendars. Additionally, 19
(1.4%) had a hysterectomy, 233 (17.7%) began using
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hormones and had no further untreated menstrual cycles
observed, and 637 (48.3%) withdrew from the study before
their FMP was identified.
The 1320 women contributed from one to 166 cycles
(median = 29) for a total of 51,606 menstrual cycles. Men-
ses duration ranged from 1 to 132 days with a mean of
5.9 days and a median of 6 days (see Supporting informa-
tion, Table S1). Menses exceeding 8 days was observed in
5287 (10.2%), menses, of 10+ days was observed in 3401
(6.6%), and menses of 15+ days in 838 (1.6%) menstrual
cycles. The range of spotting days was 0–82 days, with a
mean of 2.6 days and a median of 2 days. Spotting of
6+ days occurred in 3181 (6.2%) menstrual cycles, and in
1991 (58.5%) cycles with menses of 10+ days. The range
of heavy days during menses was 0–19 days, with a mean
of 0.7 days and a median of 0 days. Heavy bleeding of
3+ days occurred in 2746 (5.3%) of menstrual cycles but in
561 (16.5%) cycles with menses of 10+ days. Heavy bleed-
ing of 3+ days occurred in 218 (6.9%) of the menstrual
cycles with 6+ spotting days, with almost all (n = 215)
occurring in menses of 10+ days.
Cumulative percentage of prolonged menses,
prolonged spotting and heavy bleeding
In the 10.5 years of observation, the cumulative percentages
of women with at least one, two or three occurrences of
menses of 10+ days were 91.0%, 87.5%, and 77.7% (see
Supporting information, Table S2). During the early MT,
with a median duration of 3.0 years (interquartile range
[IQR] 1.3–5.3 years), the cumulative percentage of women
with at least three occurrences of menses of 10+ days was
51.6%. During the late MT, with a median duration of
2.6 years (IQR 1.8–3.9), the cumulative percentage of
women with at least three episodes of menses of 10+ days
was 54.6%. The median time between 10+-day bleeding
episodes was 125 days (IQR 54–301 days). Among women
experiencing such episodes, 27.5% experienced three
episodes within a 6-month period. Median time between
8+-day bleeding episodes was 88 days (IQR 35–197 days),
with 39.0% of women with such episodes experiencing
three 8+ day bleeding episodes within a 6-month period.
During the study, 66.8% of women had at least three
occurrences of 6+ days of spotting, with 51.2% of women
recording at least three such occurrences during the early
MT and 75.2% during the late MT. The median time
between 6+-day spotting episodes was 148 days (IQR
60–266 days). Among women experiencing three or more
episodes of spotting, 23.6% recorded three episodes within
a 6-month time window. The cumulative percentage of
women with at least three occurrences of menses with three
or more days of heavy bleeding was 34.5%, while 30.7%
and 34.7% had at least three such occurrences during the
early MT and late MT, respectively. The median time
Table 1. Baseline demographics of women who were included and
excluded from the Study of Women’s Health Across the Nation
(SWAN) Menstrual Calendar Substudy
Included
(n = 1320)
n (%)
Excluded
(n = 178)
n (%)
P value
Study site
Southeastern Michigan 430 (32.6) 113 (63.5)
Northern California 432 (32.7) 27 (15.2) <0.001
Los Angeles 458 (34.7) 38 (21.3)
Race/ethnicity
African-American 236 (17.9) 89 (50.0)
Chinese 232 (17.6) 18 (10.1) <0.001
Japanese 262 (19.8) 19 (10.7)
White 590 (44.7) 52 (29.2)
Education*
Less than High School 66 (5.0) 14 (8.6)
High School graduate 219 (16.6) 35 (21.6)
Some College/Vocation 455 (34.5) 60 (37.1) 0.01
College graduate 296 (22.4) 35 (21.6)
Post College 284 (21.5) 18 (11.1)
Marital status**
Single 172 (13.0) 22 (12.6)
Married 911 (69.1) 103 (58.9)
Separated 44 (3.3) 10 (5.7) 0.02
Widowed 24 (1.8) 6 (3.4)
Divorced 168 (12.7) 34 (19.4)
How hard is it to pay for basics***
Very hard 91 (6.9) 15 (8.8)
Somewhat hard 349 (26.4) 63 (36.8) 0.01
Not hard 880 (66.7) 93 (54.4)
BMI, kg/m2****
Normal (≤24.9) 759 (58.4) 67 (38.3)
Overweight (25.0–29.9) 251 (19.3) 54 (30.9) <0.001
Obese(≥30.0) 290 (22.3) 54 (30.9)
Baseline smoking status*****
Never 836 (64.1) 104 (59.8)
Past 277 (21.2) 31 (17.8) 0.03
Current 191 (14.7) 39 (22.4)
Ever taken hormones
before study******
154 (11.7) 17 (9.7) 0.43
Ever diabetes during
study*******
211 (16.0) 33 (18.5) 0.39
Ever fibroids during
study*******
417 (31.6) 47 (26.4) 0.17
Age at screener years,
mean (SD)
45.7 (2.7) 46.3 (3.0) 0.02
Study was conducted in three SWAN sites: Los Angeles, Northern
California, Southeastern Michigan.
*Sixteen excluded have missing information.
**One included and three excluded have missing information.
***Seven excluded have missing information.
****Twenty included and three excluded had missing information.
*****Sixteen included and four excluded had missing information.
******Does not include oral contraceptive pills.
*******Diagnosed during the first ten annual visits.
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between heavy bleeding episodes was 99 days (IQR 31–
231 days), with 39.8% of women who recorded three or
more episodes of heavy bleeding experiencing them within
a 6-month time window.
Multivariable quantile and logistic regression
Based on the multivariable quantile regression, women who
were diagnosed with uterine fibroids had a 1.00 (95% con-
fidence interval 0.17–1.83) day longer median menses dura-
tion than women who were not diagnosed with uterine
fibroids. Median menses duration was not associated with
MT stage, ethnicity, education, economic strain, diabetes,
BMI, physical activity, current smoking or reported hor-
mone use during the study.
In multivariable logistic regression models, being in the
MT was associated with menses duration of 10+ days,
6+ days of spotting and 3+ heavy bleeding days (Table 2.)
Compared with premenopausal cycles, women were more
likely to report menses of 10+ days, 6+ days of spotting, or
3+ days of heavy bleeding in both the early and late MT,
with the odds slightly higher in the late than early MT.
Women with uterine fibroids were more likely to report
each of these three types of bleeding episodes than women
not diagnosed with uterine fibroids; however, the 95% con-
fidence interval for heavy menstrual bleeding included the
null (1.00). Women who reported using hormones during
the study were also more likely to report each of the three
bleeding types than women who did not.
African-American women were less likely to report men-
ses of 10+ days or 6+ days of spotting compared with
white women. Japanese women were less likely to report
3+ days of heavy bleeding than white women. Women for
whom it was very or somewhat hard to pay for basics were
more likely to record 3+ days of heavy bleeding than other
women. Overweight women and obese women were more
likely to experience 3+ days of heavy bleeding than normal
weight women. Current smokers were more likely to record
3+ days of heavy bleeding than non-smokers.
Education, economic strain, diabetes, BMI, physical
activity or current smoking were not associated with men-
ses of 10+ days or 6+ days of spotting. In the unadjusted
analyses, both diabetes and thyroid conditions were associ-
ated with 3+ days of heavy bleeding, but the relationships
did not persist after adjustment. Education and physical
activity were not associated with 3+ days of heavy bleeding.
Among white women, study site was not associated with
Table 2. Adjusted logistic regression models for potentially abnormal uterine bleeding,3–6 The Study of Women’s Health Across the Nation
Menstrual Calendar Substudy.
Menses 10 + days* Spotting 6 + days** Heavy bleeding 3 + days***
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI)
Menopausal transition stage
Pretransition Reference Reference Reference
Early transition 3.15 (2.47–4.02) 2.66 (1.98–3.57) 1.38 (1.10–1.73)
Late transition 4.30 (3.26–5.68) 3.95 (2.83–5.52) 1.75 (1.31–2.34)
Unknown 1.46 (0.82–2.59) 0.94 (0.50–1.77) 1.41 (0.90–2.22)
Race/ethnicity
African-American 0.64 (0.46–0.89) 0.52 (0.37–0.73) 1.26 (0.87–1.84)
Chinese 0.97 (0.72–1.32) 1.23 (0.90–1.69) 1.04 (0.71–1.51)
Japanese 0.80 (0.60–1.07) 1.01 (0.76–1.34) 0.59 (0.39–0.88)
White Reference Reference Reference
Very or somewhat hard to pay for basics n/a 1.24 (0.96–1.60) 1.57 (1.17–2.11)
Uterine fibroids 1.52 (1.22–1.88) 1.28 (1.04–1.58) 1.34 (0.97–1.85)
BMI, kg/m2
Normal weight (≤24.9) Reference Reference Reference
Overweight (25.0–29.9) 0.94 (0.73–1.20) 0.88 (0.70–1.11) 1.40 (1.02–1.91)
Obese (≥30) 0.91 (0.69–1.19) 0.80 (0.58–1.10) 2.24 (1.63–3.08)
Current smoker n/a n/a 1.63 (1.16–2.28)
Ever hormone use during study 1.59 (1.27–2.00) 1.32 (1.06–1.64) 1.62 (1.21–2.16)
*Multivariable model contained menopausal transition stage, race/ethnicity, uterine fibroids, BMI, ever hormone use, and adjusted for repeated
measures.
**Multivariable model contained menopausal transition stage, race/ethnicity, hard to pay for basics, uterine fibroids, BMI, ever hormone use, and
adjusted for repeated measures.
***Mulitvariable model contains menopausal transition stage, race/ethnicity, hard to pay for basics, uterine fibroids, BMI, current smoker, ever
hormone use, and adjusted for repeated measures.
1568 ª 2014 Royal College of Obstetricians and Gynaecologists
Paramsothy et al.
menses of 10+ days, 6+ days of spotting, or 3+ days of
heavy bleeding.
Discussion
Main findings
This study is one of the first to examine the frequency of
prolonged menses and heavy bleeding during the MT and
to evaluate race/ethnicity, BMI and other factors in relation
to these menstrual events. Three out of four of these mid--
life women experienced at least three occurrences of menses
of 10+ days. Slightly more than one-quarter of these
women experienced three such bleeding episodes within a
6-month time window. Menses with spotting of 6+ days
occurred in over half the episodes of menses of 10+ days.
Menses with heavy bleeding of 3+ days were less common,
yet one in three women recorded three or more occur-
rences during their MT, approximately 40% of whom expe-
rienced three heavy bleeding episodes with a 6-month time
window.
Strengths and limitations
Study limitations included left-censoring, which may have
biased our results. The mean age of women eligible for this
study was 45.7 years and, for some women, the onset of
the MT occurred before enrolment into the study. Women
who did not have a menstrual cycle in the last 3 months
were ineligible to enrol into the SWAN cohort study, there-
fore women who were near the end of the MT, who experi-
enced surgical amenorrhoea or who had already
experienced their FMP were excluded. Nonetheless, these
data provide one of the first evaluations of the frequency
of long and heavy menses during the MT. In the popula-
tion from which our cohort study was enrolled, Afri-
can-American women were more likely to have had a
hysterectomy.29 Information on uterine fibroids was
obtained by self-report and may be underreported.
Given that these data are drawn from a population-based
study that did not include medical record linkage, a further
limitation of this study is that information on other condi-
tions that may affect uterine bleeding such as polyps or
adenomyosis was not available. Hence we could not differ-
entiate pathological from nonpathological bleeding. As we
cannot correlate these bleeding patterns with the likelihood
of specific pathology or subsequent cancer rates, these data
are informative about expected frequency of prolonged and
heavy bleeding during the menopausal transition, but
definitive inferences about threshold indications for clinical
evaluation are not possible.
Interpretation
This study is the only multi-ethnic study of menstrual
bleeding patterns during the menopausal transition and it
is based on a large sample of prospectively collected men-
strual calendar data recorded for up to 10 years. We found
that menses of 10+ days were more likely to occur during
the early and late MT than in late reproductive life. In con-
trast, the median duration of menses was not associated
with reproductive stage, suggesting that it is not the aver-
age menses length but rather the likelihood of prolonged
bleeding which changes during the MT. Our results are
consistent with previous studies and provide more compre-
hensive quantitative data. The Melbourne Women’s Midlife
Health Project did not find a change in mean heaviness of
flow from the first to second year of their study.20 The
Massachusetts Women’s Health Study found a higher per-
centage of menses exceeding 8 days in perimenopausal
women than premenopausal women.19
The FIGO Menstrual Disorders Working Group sug-
gested the normal limits for the duration of menstrual flow
in the mid-reproductive years to be between 4.5 and
8 days3,6 with prolonged menstrual bleeding defined as
bleeding exceeding 8 days. Previous recommendations
defined prolonged menstrual bleeding as 10 or more days7
or menses exceeding 14 days.8 We found that prolonged
menses of 10+ days to be common occurrences during the
menopausal transition.
Only one other calendar study, among postmenarcheal
girls, has examined ethnic differences in menstrual bleeding
in the USA. Mean duration of bleeding was a half-day less
among African-American girls compared with white girls,
but African-American girls were more likely to report
heavy bleeding.30 In our SWAN Menstrual Calendar Study,
menses of 10+ days were less likely in African-American
women compared with white women but African-American
women were more likely to experience three or more days
of heavy bleeding, although the latter association was atten-
uated in the multivariable analysis.
The BMI was associated with heaviness of flow but not
menses duration in this analysis. A similar result was seen
in a Danish study, which observed that obese women were
more likely to report menstrual flooding but not prolonged
menstrual bleeding.18 In the SWAN Daily Hormone Study,
obesity was also associated with three or more days of
heavy bleeding.31 The Michigan Bone Health and Metabo-
lism Study did not find an association between menses
duration and BMI in women aged 25–50 years.32 However,
several studies of adolescent and young adult women
report an association between low BMI and longer men-
ses30,33,34 or high BMI and short menses.30,35–37 The associ-
ations we found with obesity may be the result of the
differences seen in hormone profiles among obese women
during the MT. In the SWAN Daily Hormone Study, obese
women were shown to have longer follicular phases, so
longer duration of estrogen stimulation, but shorter luteal
phases. Obese women in the SWAN Daily Hormone Study
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had lower luteinising hormone, and progesterone metabo-
lites as well as lower follicle-stimulating hormone levels,38
as was also found in the longitudinal SWAN cohort.39
Ever being on hormones during the study was positively
associated with all three bleeding events, consistent with
the fact that hormones are used to treat alterations in uter-
ine bleeding.40 Uterine fibroids were also positively associ-
ated with all three bleeding events. In our study, women
self-reported a physician diagnosis of uterine fibroids. Typi-
cally, women are only diagnosed with uterine fibroids when
they present with a specific complaint and are evaluated.
However, it is estimated that 50% of women with uterine
fibroids are asymptomatic.41 Hence, this association may
only reflect identified uterine fibroids that cause more
symptoms.
Conclusion
We found that the large majority of women in SWAN,
over 50% of whom were not white, reported menses dura-
tion of 10+ days, spotting of 6+ days and/or 3+ days of
heavy bleeding during the MT. The likelihood of experienc-
ing these menstrual bleeding events varied by race/ethnic-
ity, BMI and reported uterine fibroids. These data confirm
that two types of bleeding, longer menses with more days
of spotting and heavier menses, occur in most women dur-
ing the MT. These data provide clinicians and women with
important normative data regarding the expected frequency
of these bleeding changes during the menopausal transi-
tion, data that may facilitate decision-making in clinical
practice. Such information, particularly when coupled with
the emerging information about duration of the stages of
the menopausal transition,25,27,42 will be of great value to
women in this life-stage who wish to be active participants
in their own health care. Such normative data can greatly
alleviate concerns about midlife changes in ones bleeding
patterns and facilitate coping with what, in most cases, will
probably be a time-limited experience. Further research on
the correlation between such bleeding and documented
pathology is warranted to better support recommendations
for watchful waiting versus clinical intervention.43
Additional studies to better define ‘normal’ bleeding pat-
terns in women aged 40–55 years should be encouraged. As
one of the only papers on menstrual bleeding patterns dur-
ing the menopausal transition, this paper provides impor-
tant information for women trying to assess changes in their
menstrual experience during the menopausal transition.
Disclosure of interests
The authors report no conflict of interest. The content of
this paper is solely the responsibility of the authors and
does not necessarily represent the official views of the
National Institutes of Health (NIH), National Institute on
Aging (NIA), the National Institute of Nursing Research
(NINR) and the NIH Office of Research on Women’s
Health (ORWH).
Contribution to authorship
Each of the authors contributed to the concept of the pro-
ject, made important contributions to the design of the
project, participated in drafting and reviewing the article
and provided expertise on menstrual cycle characteristics
and the menopausal transition. Additionally, two of the
authors (GG and JR) provided additional clinical expertise,
three of the authors provided technical expertise and super-
vised data collection at the study sites (SH, GG, EG) and
three of the authors provided expertise on statistics (SC,
ME, LL). PP conducted data programming, all statistical
analyses, and took the lead on drafting the manuscript.
Details of ethics approval
Northern California: Institutional review Board Administra-
tion, University of California at Davis 28 December 2012
(original study approval date 6 February 1996), IRB no.
260339-8 (Original protocol number 96-466R) and Institu-
tional Review Board for the Protection of Human Subjects,
Kaiser Foundation Research Institute 28 May 2013 (Origi-
nal approval date August 18, 1995) CN-94BSter-01-H.
Los Angeles: Office of Human Research Protection, Uni-
versity of California at Los Angeles, 23 May 2013 (Original
study approval date 4 May 1995), IRB#11-002274.
Southeastern Michigan: The Health Sciences and Behav-
ioral Sciences Institutional Review Boards (IRB-HSBS),
University of Michigan 20 December 2012 (Original study
approval date 1 July 2005) H03-00000531.
Funding
The Study of Women’s Health Across the Nation (SWAN)
has grant support from the National Institutes of
Health (NIH), DHHS, through the National Institute on
Aging (NIA), the National Institute of Nursing Research
(NINR) and the NIH Office of Research on Women’s
Health (ORWH) (Grants U01NR004061; U01AG012505,
U01AG012535, U01AG012531, U01AG012539, U01AG012546,
U01AG012553, U01AG012554, U01AG012495). The first
author was also supported by the ReSTAGE collaboration,
which has grant support from the NIA (Grant
R01AG021543) and the University of Michigan Rackham
Graduate School.
Acknowledgements
We thank the study staff at each site and all the women who
participated in SWAN. Clinical Centers: University of Michi-
gan, Ann Arbor – Sioban Harlow, PI 2011–present, Mary-
Fran Sowers, PI 1994-2011; Massachusetts General Hospital,
Boston, MA – Joel Finkelstein, PI 1999–present; Robert
1570 ª 2014 Royal College of Obstetricians and Gynaecologists
Paramsothy et al.
Neer, PI 1994–99; Rush University, Rush University Medical
Center, Chicago, IL – Howard Kravitz, PI 2009–present;
Lynda Powell, PI 1994–2009; University of California,
Davis/Kaiser – Ellen Gold, PI; University of California, Los
Angeles – Gail Greendale, PI; Albert Einstein College of
Medicine, Bronx, NY – Carol Derby, PI 2011–present,
Rachel Wildman, PI 2010–11; Nanette Santoro, PI 2004–10;
University of Medicine and Dentistry – New Jersey Medical
School, Newark – Gerson Weiss, PI 1994–2004; and the Uni-
versity of Pittsburgh, Pittsburgh, PA – Karen Matthews, PI.
NIH Program Office: National Institute on Aging, Bethesda,
MD – Winifred Rossi 2012–present; Sherry Sherman 1994–
2012; Marcia Ory 1994–2001; National Institute of Nursing
Research, Bethesda, MD – Program Officers. Central Labora-
tory: University of Michigan, Ann Arbor – Daniel McCon-
nell (Central Ligand Assay Satellite Services). Coordinating
Center: University of Pittsburgh, Pittsburgh, PA – Maria
Mori Brooks PI 2012–present; Kim Sutton-Tyrrell, PI 2001–
2012; New England Research Institutes, Watertown, MA –
Sonja McKinlay, PI 1995–2001. Steering Committee: Susan
Johnson, Current Chair; Chris Gallagher, Former Chair.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Number of menstrual cycles (51,606) by bleed-
ing characteristic, Study of Women’s Health Across the
Nation (SWAN) Menstrual Calendar Substudy.
Table S2. Estimated cumulative percentage and 95%
confidence interval of 1320 women with at least one, two,
or three occurrences of potentially abnormal uterine bleed-
ing,3–6 The Study of Women’s Health Across the Nation
(SWAN) Menstrual Calendar Substudy.&
References
1 Whiteman MK, Kuklina E, Jamieson DJ, Hillis SD, Marchbanks PA.
Inpatient hospitalization for gynecologic disorders in the United
States. Am J Obstet Gynecol 2010;202:e1–6.
2 Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review
evaluating health-related quality of life, work impairment, and
health-care costs and utilization in abnormal uterine bleeding. Value
Health 2007;10:183–94.
3 Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO
recommendations on terminologies and definitions for normal and
abnormal uterine bleeding. Semin Reprod Med 2011;29:383–90.
4 Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification
system (PALM-COEIN) for causes of abnormal uterine bleeding in
nongravid women of reproductive age. Int J Gynaecol Obstet
2011;113:3–13.
5 Munro MG, Critchley HO, Fraser IS. The FIGO classification of causes
of abnormal uterine bleeding in the reproductive years. Fertil Steril
2011;95:2204–8, 8 e1–3.
6 Munro MG, Critchley HO, Fraser IS. The FIGO systems for
nomenclature and classification of causes of abnormal uterine
bleeding in the reproductive years: who needs them? Am J Obstet
Gynecol 2012;207:259–65.
7 Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated
women. Task Force on Long-Acting Systemic Agents for Fertility
Regulation. Contraception 1997;55:57–65.
8 Belsey EM, Machin D, d’Arcangues C. The analysis of vaginal
bleeding patterns induced by fertility regulating methods. World
Health Organization Special Programme of Research, Development
and Research Training in Human Reproduction. Contraception
1986;34:253–60.
9 Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al.
Executive summary of the Stages of Reproductive Aging Workshop
+ 10: addressing the unfinished agenda of staging reproductive
aging. J Clin Endocrinol Metab 2012;97:1159–68.
10 Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al.
Executive summary of the Stages of Reproductive Aging Workshop
+ 10: addressing the unfinished agenda of staging reproductive
aging. Menopause 2012;19:387–95.
11 Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al.
Executive summary of the Stages of Reproductive Aging Workshop
+ 10: addressing the unfinished agenda of staging reproductive
aging. Fertil Steril 2012;97:843–51.
12 Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al.
Executive summary of the Stages of Reproductive Aging Workshop
+10: addressing the unfinished agenda of staging reproductive
aging. Climacteric 2012;15:105–14.
13 Harlow SD, Lin X, Ho MJ. Analysis of menstrual diary data across
the reproductive life span applicability of the bipartite model
approach and the importance of within-woman variance. J Clin
Epidemiol 2000;53:722–33.
14 Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the
human menstrual cycle through reproductive life. Int J Fertil 1967;12:
77–126.
15 Vollman RF. The degree of variability of the length of the menstrual
cycle in correlation with age of woman. Gynaecologia
1956;142:310–14.
16 Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss –
a population study. Variation at different ages and attempts to
define normality. Acta Obstet Gynecol Scand 1966;45:320–51.
17 Shapley M, Jordan K, Croft PR. An epidemiological survey of
symptoms of menstrual loss in the community. Br J Gen Pract
2004;54:359–63.
18 Astrup K, Olivarius Nde F, Moller S, Gottschau A, Karlslund W.
Menstrual bleeding patterns in pre- and perimenopausal women: a
population-based prospective diary study. Acta Obstet Gynecol
Scand 2004;83:197–202.
19 Johannes CB, Crawford SL, Longcope C, McKinlay SM. Bleeding
patterns and changes in the perimenopause: a longitudinal
characterization of menstrual cycles. Clin Consult Obstet Gyncecol
1996;8:9–20.
20 Taffe J, Dennerstein L. Retrospective self-report compared with
menstrual diary data prospectively kept during the menopausal
transition. Climacteric 2000;3:183–91.
21 Sowers M, Crawford S, Sternfeld B, Morganstein D, Gold E,
Greendale G, et al. SWAN: a multicenter, multiethnic,
community-based cohort study of women and the menopausal
transition. In: Lobo RA, Kelsey J, Marcus R, editors. Menopause:
Biology and Pathobiology. San Diego: Academic Press; 2000. pp.
175–88.
1571ª 2014 Royal College of Obstetricians and Gynaecologists
Menstruation and the menopausal transition
22 Geller SE, Harlow SD, Bernstein SJ. Differences in menstrual
bleeding characteristics, functional status, and attitudes toward
menstruation in three groups of women. J Womens Health Gend
Based Med 1999;8:533–40.
23 Belsey EM, Carlson N. The description of menstrual bleeding
patterns: towards fewer measures. Stat Med 1991;10:267–84.
24 Belsey EM, Farley TM. The analysis of menstrual bleeding patterns: a
review. Contraception 1988;38:129–56.
25 Harlow SD, Cain K, Crawford S, Dennerstein L, Little R, Mitchell ES,
et al. Evaluation of four proposed bleeding criteria for the onset of
late menopausal transition. J Clin Endocrinol Metab 2006;91:3432–
8.
26 Harlow SD, Crawford S, Dennerstein L, Burger HG, Mitchell ES,
Sowers MF. Recommendations from a multi-study evaluation of
proposed criteria for staging reproductive aging. Climacteric
2007;10:112–19.
27 Harlow SD, Mitchell ES, Crawford S, Nan B, Little R, Taffe J. The
ReSTAGE Collaboration: defining optimal bleeding criteria for onset
of early menopausal transition. Fertil Steril 2008;89:129–40.
28 Koenker R. Quantile Regression. Cambridge: Cambridge University
Press; 2005.
29 Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA,
Harlow SD, et al. Factors associated with age at natural menopause
in a multiethnic sample of midlife women. Am J Epidemiol
2001;153:865–74.
30 Harlow SD, Campbell B. Ethnic differences in the duration and
amount of menstrual bleeding during the postmenarcheal period.
Am J Epidemiol 1996;144:980–8.
31 Van Voorhis BJ, Santoro N, Harlow S, Crawford SL, Randolph J.
The relationship of bleeding patterns to daily reproductive
hormones in women approaching menopause. Obstet Gynecol
2008;112:101–8.
32 Sternfeld B, Jacobs MK, Quesenberry CP Jr, Gold EB, Sowers M.
Physical activity and menstrual cycle characteristics in two
prospective cohorts. Am J Epidemiol 2002;156:402–9.
33 Cooper GS, Klebanoff MA, Promislow J, Brock JW, Longnecker MP.
Polychlorinated biphenyls and menstrual cycle characteristics.
Epidemiology 2005;16:191–200.
34 Harlow SD, Campbell BC. Host factors that influence the duration of
menstrual bleeding. Epidemiology 1994;5:352–5.
35 Belsey EM, Peregoudov S. Determinants of menstrual bleeding
patterns among women using natural and hormonal methods of
contraception. I. Regional variations. Contraception 1988;38:227–42.
36 Cooper GS, Sandler DP, Whelan EA, Smith KR. Association of
physical and behavioral characteristics with menstrual cycle patterns
in women age 29-31 years. Epidemiology 1996;7:624–8.
37 Lin HT, Lin LC, Shiao JS. The impact of self-perceived job stress on
menstrual patterns among Taiwanese nurses. Ind Health
2007;45:709–14.
38 Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold
EB, et al. Body size and ethnicity are associated with menstrual cycle
alterations in women in the early menopausal transition: The Study
of Women’s Health across the Nation (SWAN) Daily Hormone Study.
J Clin Endocrinol Metab 2004;89:2622–31.
39 Randolph JF Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold
EB, et al. Change in follicle-stimulating hormone and estradiol
across the menopausal transition: effect of age at the final
menstrual period. J Clin Endocrinol Metab 2011;96:746–54.
40 Jain A, Santoro N. Endocrine mechanisms and management for
abnormal bleeding due to perimenopausal changes. Clin Obstet
Gynecol 2005;48:295–311.
41 Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best
Pract Res Clin Obstet Gynaecol 2008;22:615–26.
42 Huang X, Harlow SD, Elliott MR. Distinguishing 6 population
subgroups by timing and characteristics of the menopausal
transition. Am J Epidemiol 2012;175:74–83.
43 American College of Obstetricians and Gynecologists. Practice
Bulletin Number 136, July 2013: management of Abnormal Uterine
Bleeding Associated with Ovulatory Dysfunction. Obstet Gynecol
2013;1222:176–85.
1572 ª 2014 Royal College of Obstetricians and Gynaecologists
Paramsothy et al.
